Allogene Therapeutics Inc.
ALLO
NGS
Sector: Healthcare
Industry: Biotechnology
9.46
USD
0.09
(0.96%)
Optionable: Yes Market Cap: 1,343 M 90-day average vol: 1,870,939
Previous close: 9.37 Open: 9.26 Bid: 9.45 Ask: 9.45
52 week range
6.43 19.11
Last updated: Monday 5th December 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 5,435.61 |
Price per Book TTM ($) | 2.00 |
PE Ratio (TTM) | -4.70 |
Book Value per Share ($) | 5.13 |
5 Year PE Range-14.1 |
Returns
7 Day Return | -7.80% | |
1 Month Return | 1.28% | |
3 Month Return | -31.65% | |
1 Year Return | -45.06% | |
3 Year Return | -67.98% | |
5 Year Return | -62.16% | |
YTD Return | -36.60% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 43.66 |
14 Day SMA ($) | 10.01 |
14 Day EMA ($) | 9.89 |
Money Flow Index | 52.33 |
Average True Range | 0.75 |
50 Day SMA ($) | 10.22 |
200 Day SMA ($) | 10.68 |
ADX | 45.36 |
MACD | -0.17 |
Growth
Free Cash Flow QoQ Growth | 9.05% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 11.54% |
Revenue QoQ Growth | -43.02% |
EPS YoY Growth | 0.00% |
Profitability
News
Financials
ALLO Income Statement
Annual
| Invalid date | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 38 M | |
| Cost of sales | 0 | -464000 | -1 M | -11 M | -17 M | |
| Gross operating profit | 0 | 0 | 0 | 0 | 38 M | |
| Selling Gen & administrative expense | 2000 | 41 M | 57 M | 65 M | 74 M | |
| Research & development expense | 0 | 152 M | 145 M | 193 M | 220 M | |
| Operating income | -2000 | -193 M | -202 M | -258 M | -256 M | |
| floaterest income | 0 | 0 | 0 | 0 | 0 | |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | |
| Other income net | 0 | -21 M | -268000 | -1 M | -3 M | |
| Pre-tax Income (EBT) | -2000 | -212 M | -185 M | -250 M | -257 M | |
| Income taxes | 0 | -117000 | -331000 | 0 | 0 | |
| Net income from total operations | -2000 | -212 M | -185 M | -250 M | -257 M | |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | |
| Total net income | -2000 | -212 M | -185 M | -250 M | -257 M | |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | |
| Net income available for common | -2000 | -212 M | -185 M | -250 M | -257 M | |
| Depreciation | 0 | 464000 | 1 M | 11 M | 17 M | |
| Amortization | 0 | 0 | 0 | 0 | 0 | |
| Operating income before depreciation (EBITDA) | -2000 | -207 M | -180 M | -251 M | -245 M | |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | |
| Basic EPS total | 0 | -7.31 | -1.83 | -2.08 | -1.89 | |
| Diluted EPS total | 0 | -7.31 | -1.83 | -2.08 | -1.89 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and starter sheets.
Get started today
Get started today